Rituximab

SAN DIEGO — Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind trial presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Paolo Caimi, MD, spoke with Healio about the latest results from the POLARIX trial presented at ASH Annual Meeting and Exposition.

WASHINGTON — In this video, Ambreesh Chawla, MD, summarizes salient and practice-changing presentations in rheumatoid arthritis from ACR Convergence 2024.

Clinical trial results in Sjögren’s disease over the last decade have volleyed between encouraging successes and deflating failures, but with several new drugs advancing through the pipeline, hopes are high yet again.

In this video, John H. Stone, MD, MPH, professor of medicine at Harvard Medical School, the Edward A. Fox Chair in Medicine at Massachusetts General Hospital, discusses an important facet of IgG4-related disease other rheumatologists and providers should be aware of.

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, highlights an observational study investigating the impact of disease-modifying antirheumatic drugs on rheumatoid arthritis-associated interstitial lung disease.

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, discusses two translational studies focused on human tissue for the treatment of rheumatoid arthritis.

The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or refractory follicular lymphoma, according to the agent’s manufacturer.

Ongoing research into the disease processes of lupus has yielded an increased number of therapeutic targets, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

An growing therapeutic armamentarium for antineutrophil cytoplasmic antibody-associated vasculitis — including avacopan and azathioprine — is providing rheumatologists with an increasingly robust array of options, according to a presenter.